Dimeric TF antagonist
OwnerMarianne Kjalke, Palle Jakobsen +1inventors
InventorsMarianne Kjalke, Palle Jakobsen, Henning Ralf Stennicke
Life of this patent
Estimating the term…
Abstract
Dimer FVII polypeptides, which binds and inhibits two TF molecules simultaneously.
Claims25
A compound having the formula A-(LM)-D, wherein A and D are FVII polypeptides that bind to tissue factor (TF);
- and LM is a linker moiety with a molecular weight less than 30,000 daltons;
- and wherein said compound inhibits TF activity, with the proviso that the compound does not have the formula:
- wtFVIIai-(DPTA-dim-FFR-cmk)-wtFVIIai or FVIIai(Q10E32)-(DPTA-dim-FFR-cmk)-FVIIai(Q10E32).
A method for reducing TF activity, said method comprising contacting a TF expressing cell with a compound having the formula A-(LM)-D, wherein A and D are FVII polypeptides that binds to TF;
- and LM is a linker moiety with a molecular weight less than 30,000 daltons;
- and wherein said compound inhibits TF activity, with the proviso that the compound does not have the formula wtFVIIai-(DPTA-dim-FFR-cmk)-wtFVIIai or FVIIai(Q10E32)-(DPTA-dim-FFR-cmk)-FVIIai(Q10E32).
A pharmaceutical composition comprising a compound having the formula A-(LM)-D, wherein A and D are FVII polypeptides that binds to TF;
- and LM is a linker moiety with a molecular weight less than 30,000 daltons;
- and wherein said compound inhibits TF activity, with the proviso that the compound does not have the formula wtFVIIai-(DPTA-dim-FFR-cmk)-wtFVIIai or FVIIai(Q10E32)-(DPTA-dim-FFR-cmk)-FVIIai(Q10E32);
- and a pharmaceutically acceptable carrier or excipient.
A compound for use as a medicament having the formula A-(LM)-D, wherein A and D are FVII polypeptides that binds to TF;
- and LM is a linker moiety with a molecular weight less than 30,000 daltons;
- and wherein said compound inhibits TF activity, with the proviso that the compound does not have the formula wtFVIIai-(DPTA-dim-FFR-cmk)-wtFVIIai or FVIIai(Q10E32)-(DPTA-dim-FFR-cmk)-FVIIai(Q10E32).
Use of a compound having the formula A-(LM)-D, wherein A and D are FVII polypeptides that binds to TF;
- and LM is a linker moiety with a molecular weight less than 30,000 daltons;
- and wherein said compound inhibits TF activity with the proviso that the compound is not a compound having the formula of wtFVIIai-(DPTA-dim-FFR-cmk)-wtFVIIai or FVIIai(Q10E32)-(DPTA-dim-FFR-cmk)-FVIIai(Q10E32) for the manufacture of a medicament for preventing or treating a TF related diseases or disorders.
A method for prevention or treatment of TF related diseases or disorders in a mammal, which method comprises administering to a mammal an effective amount for said prevention or treatment of at least one compound having the formula A-(LM)-D, wherein A and D are FVII polypeptides that bind to TF;
- and LM is a linker moiety with a molecular weight less than 30,000 daltons;
- and wherein said compound inhibits TF activity, with the proviso that the compound does not have the formula wtFVIIai-(DPTA-dim-FFR-cmk)-wtFVIIai or FVIIai(Q10E32)-(DPTA-dim-FFR-cmk)-FVIIai(Q10E32).
Dependencies are inferred from the claim text.